Literature DB >> 3504058

7 alpha-substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase.

R W Brueggemeier1, P K Li, C E Snider, M V Darby, N E Katlic.   

Abstract

Research efforts over the past several years have focused on the synthesis of competitive and irreversible aromatase inhibitors and examination of these inhibitors in microsomal preparations, in cell culture, and in vivo. Several 7 alpha-substituted androstenediones have demonstrated high affinity for placental aromatase, with apparent Ki's ranging from 1 to 30 nM. Inactivation of aromatase occurred following incubation with alkylating and enzyme-activated irreversible inhibitors. 7 alpha-(4'-Amino)phenylthio-4-androstene-3,17-dione (7 alpha-APTA) exhibits potent inhibitory activity of aromatase in the MCF-7 human mammary carcinoma cell line with an ED50 of approximately 25 nM. The inhibitor did not bind to the estrogen receptor of the cells in vitro nor induce levels of progesterone receptors in intact cells. In vivo studies of 7 alpha-APTA in the DMBA-induced rat mammary carcinoma model resulted in 80% of the tumors responding completely or partially at doses of 25 and 50 mg/kg body wt/day. Thus, these 7 alpha-substituted steroidal aromatase inhibitors are effective medicinal agents and may be useful for the treatment of estrogen-dependent breast cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3504058     DOI: 10.1016/0039-128x(83)90069-7

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  4 in total

Review 1.  Aromatase inhibitors--mechanisms of steroidal inhibitors.

Authors:  R W Brueggemeier
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro.

Authors:  Megan Cavanaugh Terp; Finn Bauer; Yasuro Sugimoto; Bo Yu; Robert W Brueggemeier; L James Lee; Robert J Lee
Journal:  Int J Pharm       Date:  2012-04-15       Impact factor: 5.875

Review 3.  Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

Authors:  V Craig Jordan; Angela M H Brodie
Journal:  Steroids       Date:  2006-12-13       Impact factor: 2.668

Review 4.  Aromatase and its inhibitors in breast cancer treatment--overview and perspective.

Authors:  A M Brodie; R J Santen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.